Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19

The novel coronavirus 2019 (COVID-19) has affected nearly every country worldwide. Reports note increased thromboembolic events among hospitalized patients and anecdotal observations of improved outcomes with systemic anticoagulation (AC). However the specific role of AC in disease management remains unclear. We assessed association between administration of in-hospital AC and survival in a large cohort of hospitalized patients with COVID-19. This work was approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai (#20-03271)